These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 28991513)

  • 1. Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.
    Long GV; Eroglu Z; Infante J; Patel S; Daud A; Johnson DB; Gonzalez R; Kefford R; Hamid O; Schuchter L; Cebon J; Sharfman W; McWilliams R; Sznol M; Redhu S; Gasal E; Mookerjee B; Weber J; Flaherty KT
    J Clin Oncol; 2018 Mar; 36(7):667-673. PubMed ID: 28991513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
    Long GV; Flaherty KT; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Chiarion-Sileni V; Lebbe C; Mandalà M; Millward M; Arance A; Bondarenko I; Haanen JBAG; Hansson J; Utikal J; Ferraresi V; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; Davies MA; Lane SR; Legos JJ; Mookerjee B; Grob JJ
    Ann Oncol; 2017 Jul; 28(7):1631-1639. PubMed ID: 28475671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma.
    Si L; Zhang X; Shin SJ; Fan Y; Lin CC; Kim TM; Dechaphunkul A; Maneechavakajorn J; Wong CS; Ilankumaran P; Lee DY; Gasal E; Li H; Guo J
    Eur J Cancer; 2020 Aug; 135():31-38. PubMed ID: 32534242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
    Robert C; Grob JJ; Stroyakovskiy D; Karaszewska B; Hauschild A; Levchenko E; Chiarion Sileni V; Schachter J; Garbe C; Bondarenko I; Gogas H; Mandalá M; Haanen JBAG; Lebbé C; Mackiewicz A; Rutkowski P; Nathan PD; Ribas A; Davies MA; Flaherty KT; Burgess P; Tan M; Gasal E; Voi M; Schadendorf D; Long GV
    N Engl J Med; 2019 Aug; 381(7):626-636. PubMed ID: 31166680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.
    Johnson DB; Flaherty KT; Weber JS; Infante JR; Kim KB; Kefford RF; Hamid O; Schuchter L; Cebon J; Sharfman WH; McWilliams RR; Sznol M; Lawrence DP; Gibney GT; Burris HA; Falchook GS; Algazi A; Lewis K; Long GV; Patel K; Ibrahim N; Sun P; Little S; Cunningham E; Sosman JA; Daud A; Gonzalez R
    J Clin Oncol; 2014 Nov; 32(33):3697-704. PubMed ID: 25287827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dabrafenib plus trametinib in patients with BRAF
    Davies MA; Saiag P; Robert C; Grob JJ; Flaherty KT; Arance A; Chiarion-Sileni V; Thomas L; Lesimple T; Mortier L; Moschos SJ; Hogg D; Márquez-Rodas I; Del Vecchio M; Lebbé C; Meyer N; Zhang Y; Huang Y; Mookerjee B; Long GV
    Lancet Oncol; 2017 Jul; 18(7):863-873. PubMed ID: 28592387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.
    Long GV; Weber JS; Infante JR; Kim KB; Daud A; Gonzalez R; Sosman JA; Hamid O; Schuchter L; Cebon J; Kefford RF; Lawrence D; Kudchadkar R; Burris HA; Falchook GS; Algazi A; Lewis K; Puzanov I; Ibrahim N; Sun P; Cunningham E; Kline AS; Del Buono H; McDowell DO; Patel K; Flaherty KT
    J Clin Oncol; 2016 Mar; 34(8):871-8. PubMed ID: 26811525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib.
    Saiag P; Robert C; Grob JJ; Mortier L; Dereure O; Lebbe C; Mansard S; Grange F; Neidhardt EM; Lesimple T; Machet L; Bedane C; Maillard H; Dalac-Rat S; Nardin C; Szenik A; Denden A; Dutriaux C
    Eur J Cancer; 2021 Sep; 154():57-65. PubMed ID: 34243078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials.
    Long GV; Grob JJ; Nathan P; Ribas A; Robert C; Schadendorf D; Lane SR; Mak C; Legenne P; Flaherty KT; Davies MA
    Lancet Oncol; 2016 Dec; 17(12):1743-1754. PubMed ID: 27864013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i.
    Dummer R; Lebbé C; Atkinson V; Mandalà M; Nathan PD; Arance A; Richtig E; Yamazaki N; Robert C; Schadendorf D; Tawbi HA; Ascierto PA; Ribas A; Flaherty KT; Pakhle N; Campbell CD; Gusenleitner D; Masood A; Brase JC; Gasal E; Long GV
    Nat Med; 2020 Oct; 26(10):1557-1563. PubMed ID: 33020648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved overall survival in melanoma with combined dabrafenib and trametinib.
    Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
    N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
    Long GV; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Grob JJ; Chiarion Sileni V; Lebbe C; Mandalà M; Millward M; Arance A; Bondarenko I; Haanen JB; Hansson J; Utikal J; Ferraresi V; Kovalenko N; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; DeMarini DJ; Irani JG; Casey M; Ouellet D; Martin AM; Le N; Patel K; Flaherty K
    N Engl J Med; 2014 Nov; 371(20):1877-88. PubMed ID: 25265492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
    Long GV; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Schadendorf D; Lesimple T; Plummer R; Ji R; Zhang P; Mookerjee B; Legos J; Kefford R; Dummer R; Kirkwood JM
    N Engl J Med; 2017 Nov; 377(19):1813-1823. PubMed ID: 28891408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF
    Schadendorf D; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Lesimple T; Plummer R; Schachter J; Dasgupta K; Manson S; Koruth R; Mookerjee B; Kefford R; Dummer R; Kirkwood JM; Long GV
    Lancet Oncol; 2019 May; 20(5):701-710. PubMed ID: 30928620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF
    Schreuer M; Jansen Y; Planken S; Chevolet I; Seremet T; Kruse V; Neyns B
    Lancet Oncol; 2017 Apr; 18(4):464-472. PubMed ID: 28268064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II).
    Atkinson V; Sandhu S; Hospers G; Long GV; Aglietta M; Ferrucci PF; Tulyte S; Cappellini GCA; Soriano V; Ali S; Poprach A; Cesas A; Rodriguez-Abreu D; Lau M; de Jong E; Legenne P; Stein D; King B; van Thienen JV
    Melanoma Res; 2020 Jun; 30(3):261-267. PubMed ID: 31895752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected
    Hauschild A; Dummer R; Schadendorf D; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Lesimple T; Plummer R; Dasgupta K; Haas T; Shilkrut M; Gasal E; Kefford R; Kirkwood JM; Long GV
    J Clin Oncol; 2018 Dec; 36(35):3441-3449. PubMed ID: 30343620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interim analysis for post-marketing surveillance of dabrafenib and trametinib combination therapy in Japanese patients with unresectable and metastatic melanoma with BRAF V600 mutation.
    Teshima Y; Kizaki M; Kurihara R; Kano R; Harumiya M
    Int J Clin Oncol; 2020 Oct; 25(10):1870-1878. PubMed ID: 32699976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
    Flaherty KT; Infante JR; Daud A; Gonzalez R; Kefford RF; Sosman J; Hamid O; Schuchter L; Cebon J; Ibrahim N; Kudchadkar R; Burris HA; Falchook G; Algazi A; Lewis K; Long GV; Puzanov I; Lebowitz P; Singh A; Little S; Sun P; Allred A; Ouellet D; Kim KB; Patel K; Weber J
    N Engl J Med; 2012 Nov; 367(18):1694-703. PubMed ID: 23020132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.